secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001171843-23-001548
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos reports FY2022 net loss of $96M; provides pipeline updates for NASH, COVID-19, HBV
--------------------------------------------------------------------------------

- Net loss FY2022 $96.0M ($2.25/share) vs $128.3M ($3.22) in FY2021; cash $125.8M as of Dec 31, 2022.
- NASH candidate ALG-055009 Phase 1 data positive; on track for Phase 2 filing by end 2023.
- COVID-19 candidate ALG-097558 to enter clinic in Q2 2023; top line data expected Q4 2023.
- HBV CAM-E ALG-000184 shows HBsAg reductions; 48-week data expected in 2023.
- HBV siRNA ALG-125755 SAD in healthy volunteers completed; now evaluating in CHB subjects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184323001548/0001171843-23-001548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184323001548/f8k_030923.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-001548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer